Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The tenure of contract will be upto 10 years from date of signing the contract/installation.
Merck’s first microbiology application and training lab in India
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
An algorithm based testing for Fatty Liver Disease
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Expanding diagnostics footprint in East India
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Amarex Clinical Research guides its client to phase II of FDA trials
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
